Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: Dale Baker who wrote (8523)	4/16/2002 10:22:26 AM
From: BDR	Respond to of 10293

Don't forget my old favorite, Vivus, which is trying to get traction with its female sexual dysfunction drug (which has the same active ingredient as MUSE) and its late-to-the-party oral erectile dysfunction drug. Someone pointed me to coverage by a broker that included such howlers as: <<He said that the reason that Muse suffered so badly in the wake of Viagra was that Muse was only available through urologists, while Viagra could be prescribed by general practitioners, a development he attributed to awareness of the widespread problem of erectile dysfunction caused by the success of Muse. >> What baloney! Anyone could prescribe MUSE. Viagra works in the majority of patients, MUSE doesn't and they fudged the data they presented to the FDA to get even the pathetic response rates that they reported. They got some mileage out of the fact that some Phase II data will be presented at the AUA: <<One event cited is the company's scheduled presentation at the annual meeting of the American Urology Association on May 27, when Vivus is expected to provide a detailed analysis of the data from the phase II study of Alista that cleared the way for Wednesday's news. >> Here is the abstract for the presentation (only one of about 1500 to be presented over five days, though you would think the meeting was being called to hear Vivus's presentation). As is usual with Vivus, there is less here than the publicity suggests, but that shouldn't surprise anyone. Executive summary: Older women become more aroused while watching X-rated movies when they use Vivus's product. In-clinic evaluation of the safety and efficacy of topical alprostadil (PGE1) for the treatment of female sexual dysfunction Marc Gittelman et al. Introduction and objectives: Female sexual dysfunction (FSD) is a common condition, occurring in over 40% of the general population. Unlike male sexual dysfunction, there are no FDA approved pharmacological treatments for female sexual dysfunction. FSD includes disorders of desire, arousal, orgasm and pain. A placebo-controlled, randomized multi-center study was conducted to evaluate the effects of topical alprostadil solution for the treatment of female sexual arousal disorder (FSAD). Methods: Women with FSAD were randomized to receive 100 or 400 micrograms of alprostadil solution or placebo. All women were either postmenopausal or had received a hysterectomy and bilateral oophorectomy. All patients had stable hormonal replacement. Treatment solution was applied to the clitoris and allowed to spread to the surrounding tissues. Patients recorded their responses to sexually explicit videos designed to elicit a sexual response. These responses included patient assessment of genital wetness/lubrication, pelvic fullness, pelvic warmth/tingling, level of sexual arousal, and the level of sexual satisfaction. In addition, investigators assessed the presence of genital erythema and edema subsequent to treatment as well as blood pressure and pulse for two hours following dosing. Results: Seventy-eight women were randomized in a 50:50 distribution to receive either topical alprostadil of placebo. Sixty-seven percent of the women treated in this study were postmenopausal. Mean patient age was 55 years (range40-70). Topical treatment with alprostadil was well tolerated with no reports of any significant systemic side effects. Compared to placebo, both doses of alprostadil were associated with increased vulvar erythema and edema, suggesting increased localized blood flow. There was no difference in responses between postmenopausal women and women who had undergone hysterectomy/oophorectomy. Subjective responses were not dose dependent. Conclusions: Topical alprostadil applied to the clitoris and vulva was associated with subjective and objective sexual response in postmenopausal and hysterectomized/oophorectomized patients with FSAD. Topical alprostadil may be an appropriate on-demand treatment for women suffering from FSAD. <<<<<<<< I don't know what Muse or Alista can do, but stock touts pumping VVUS give me a feeling of warmth and tingling. It makes me feel young again. Or at least as young as I was in 1997: siliconinvestor.com